
COPY FOR IB





101

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Artcle 36 and Rule 70) Rec'd PCT/PTG 12 OCT 2004

Applicant's or agent's file reference PCT0087	FOR FURTHER ACTION	FOR FURTHER ACTION SeeNotificationofTransmittalofInternat Examination Report (Form PCT/IPEA/		nalPreliminary 16)	
International application No.	International filing date(day/mor	th/year)	Priority date (day/month)	(year)	
PCT/KR2002/000617	09 APRIL 2002 (09.04.20	002)			
International Patent Classification (IPC) or national classification and IPC	:			
IPC7 C12P 1/00					
10, 0121 1/0					
	· V				
Applicant					
GENOFOCUS CO., LTD. et	al				
	examination report has been prepa	mad by this Inte	ernational Preliminary Exar	nining Authority	
This international preliminary earlies and is transmitted to the application.	examination report has been preparation at according to Article 36.	icu by uns mo	Jimunoimi i i i i i i i i i i i i i i i i i i		
		ling this cover s	heet.		
2. This REPORT consists of a tota	of sheets, include panied by ANNEXES, i.e., sheets	of the descripti	on, claims and/or drawings	which have been	
amended and are the basis	s for this report and/or sheets con	taining rectifica	tions made before this Au	thority (see Rule	
70.16 and Section 607 of	the Administrative Instructions un	der the PCT).			
These annexes consist of a tota	l ofsheets.				
3. This report contains indications	3. This report contains indications relating to the following items:				
I X Basis of the report	I X Basis of the report				
II Priority					
1 1 1	t of opinion with regard to novelty	, inventive step	and industrial applicability		
IV Lack of unity of in					
V X Reasoned stateme	ent under Article 35(2) with regard	l to novelty, inv	entive step or industrial app	olicability;	
Citations and expi	anations supporting such statemen	t			
VI Certain document					
	the international application				
VIII Certain observation	ons on the international application	1			
Date of submission of the demand	Date	e of completion	of this report		
			004 (20 07 2004)		
10 NOVEMBER 2003 (10.11	1,2003)	30 JULY 2	004 (30.07.2004)		
Name and mailing address of the IPE		horized officer		(1)(人)	
Korean Intellectual Prop 920 Dunsan-dong, Seo-	erty Office gu, Daejeon 302-701,	WON, Jong I	łyeok	り、一つ、	
Republic of Korea				(しつ)	
Facsimile No. 82-42-472-7140	. [Tel	ephone No. 82	-42-481-3392		



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Intern	l aplication No.
PCT/KR	2002/000617

Ī	. Basis	s of the report	
1.	With	regard to the elements of the international application:*	
	X	the international application as originally filed	
	$\overline{\mathbf{x}}$	the description:	
	<u>:</u>	pages <u>1-45</u>	, as originally filed
		pages — — — — — — — — — — — — — — — — — — —	, filed with the demand
	_	pages, filed with the letter of	
	X	the claims: pages 46-57	, as originally filed
		pages, as amended (together with any	y statment) under Article 19
		pages, filed with the letter of	, filed with the demand
	₩		
	X	the drawings: pages 1/12- 12/12	_ , as originally filed
		pages	, filed with the demand
	$\overline{}$	pages, filed with the letter of	
	Ш	the sequence listing part of the description:	
		pagespages	
		pages, filed with the letter of	,
2.	the i	h regard to the language, all the elements marked above were available or furnished to this Authoritemational application was filed, unless otherwise indicated under this item. se elements were available or furnished to this Authority in the following language Englist the language of a translation furnished for the purposes of international search (under Rule 23. the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examinor 55.3).	which is 1(b)).
3.	Wit	th regard to any nucleotide and/or amino acid sequence disclosed in the international appli liminary examination was carried out on the basis of the sequence listing: contained inthe international application in written form.	cation, the international
	닏	filed together with the international application in computer readable form.	
		furnished subsequently to this Authority in written form.	
		furnished subsequently to this Authority in computer readable form	
		The statement that the subsequently furnished written sequence listing does not go bey international applicationas as filed has been furnished. The statement that the information recorded in computer readable form is identical to the w been furnished.	
4.	П	The amendments have resulted in the cancellation of:	
		the description, pages the claims, Nos.	
		the drawings, sheet	
5.			
		This report has been established as if (some of) the amendments had not been made, since t go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2(c)).**	hey have been considered to
	Replac in this and 70	cement sheets which have been furnished to the receiving Office in response to an invitation una opinion as "originally filed." and are not annexed to this report since they do not contain to 0.17).	ler Article 14 are referred to amendments (Rules 70.16
**	Any re	eplacement sheet containing such amendments must be referred to under item I and annexed to	this report.

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1				
1.	Statement			
	Novelty (N)	Claims	1-56	YES
		Claims	None	NO
	Inventive step (IS)	Claims	1-56	YES
		Claims	None	NO
	Industrial applicability (IA)	Claims	1-56	
		Claims	None -	NO

2. Citations and explanations (Rule 70.7)

1) Reference is made to the following documents identified in the International Search Report:

D1: J. of Bacteriology, Vol. 183, No. 21, pages 6294-6301 (2001)

D2: WO 02-00232 A D3: WO 01-12817 A

2) D1 discloses the surface display system based on the use of bacterial spores. A protein of the *Bacillus* subtillis spore coat was found to be located on the spore surface and used as fusion partner to express the amino acid terminal fragment of the tetanus toxin.

D2 discloses the method for modulation of an immune response of an organism comprising contacting organism with a spore system and comprising a recombinant spore having at least one exogenous nucleic acid, peptide, or polypeptide. In this invention, the nucleic acid, peptide, or polypeptide is displayed on or bound to a surface of the spore.

D3 discloses the libraries of recombinant enzymes that are useful for biocatalytic synthesis of derivatives of organic molecules. The use of recombinant enzyme libraries enables to obtain enzymes that catalyze the formation of organic molecule derivatives.

3) The subject-matter of Claim 1 to Claim 2 differs from the process of the closest prior art, which is defined by D1, in the use of a biocatalyst which comprises the steps of preparing a vector for spore surface display comprising a gene construct containing a gene encoding a display motif and a gene encoding the biocatalyst. And none of the cited prior art discloses the biocatalyst according to Claim 29 and Claim 30 which fused covalently to a display motif or displayed on virus surface by virtue of noncovalent bonds.

The prior art provides surface display of recombinant proteins on microbial organism spores. The biocatalyst described in the prior art cannot be continuously reused and applied to various bioconversion reactions because many problems such as cell disruption, inactivation of biocatalyst due to protease may occur during bioconversion reaction.

Meanwhile, the method of Claim 1 to Claim 2 using the stabilized biocatalyst according to Claim 29 to Claim 30 displayed on the surface of virus allows to reuse continuously for a long time and to have various resistance to extreme environment and to be applicable to various bioconversion reactions.

As a consequence, the subject-matter of Claim 1 to 2 and Claim 29 to 30 and its dependent Claim 3 to 28 and 31 to 56 is novel and inventive over the cited prior art. Therefore, the subject-matter of Claims 1 to 56 would appear to meet the requirements of Article 33(2) and 33(3) PCT.

4) It would appear that the claimed subject-matter is industrially applicable.

Therefore, the subject-matter of Claims 1 to 56 meets the requirements of Article 33(4) PCT.